AEON · AEON BIOPHARMA INC

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

5 Park Plaza, Irvine, CA, 92614, United States
Biotechnology
Healthcare

Market Cap

10.06M

52 Wk Range

$0.13 - $1.45

Previous Close

$0.14

Open

$0.16

Volume

4,348,801

Day Range

$0.16 - $0.16

Enterprise Value

9.406M

Cash

3.431M

Avg Qtr Burn

-3.698M

Insider Ownership

54.32%

Institutional Own.

23.71%

Qtr Updated

Jun 30th 2026